Description
Recombinant Human OLFM4 Protein (His Tag) | PKSH033360 | Gentaur US, UK & Europe Disrtribition
Synonyms: Olfactomedin-4; OLM4; Antiapoptotic protein GW112; G-CSF-stimulated clone 1 protein; hGC-1; hOLfD; OLFM4; GW112
Active Protein: N/A
Activity: Recombinant Human Olfactomedin-4 is produced by our Mammalian expression system and the target gene encoding Asp21-Gln510 is expressed with a 10His tag at the C-terminus.
Protein Construction: Recombinant Human Olfactomedin-4 is produced by our Mammalian expression system and the target gene encoding Asp21-Gln510 is expressed with a 10His tag at the C-terminus.
Fusion Tag: C-6His
Species: Human
Expressed Host: Human Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 80 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 56.9 kDa
Formulation: Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
Reconstitution: Please refer to the printed manual for detailed information.
Background: Olfactomedin-4/OLFM4 is a secreted protein which contains one olfactomedin-like domain. OLFM4 is expressed during myeloid lineage development;it strongly expressed in the prostate;small intestine;colon and moderately expressed in the bone marrow and stomach. OLFM4 is an antiapoptotic factor that promotes tumor growth. It expressed at high levels in stomach cancer and colon cancer tissues. it promotes proliferation of pancreatic cancer cells by favoring the transition from the S to G2/M phase. In myeloid leukemic cell lines; OLFM4 inhibits cell growth and induces cell differentiation and apoptosis. Through interaction with cell surface lectins and cadherin; OLFM4 facilitates cell adhesion. It may play a role in the inhibition of EIF4EBP1 phosphorylation/deactivation. Induction of OLFM4 in cancer cells was reported to have a novel antiapoptotic action via binding to the potent apoptosis inducer GRIM-19.
Research Area: Cancer
